المؤلفون: Spiliopoulou, Pavlina, Kazmi, Farasat, Aroldi, Francesca, Holmes, Thomas, Thompson, David, Griffiths, Lucinda, Qi, Cathy, Parkes, Matthew, Lord, Simon, Veal, Gareth J., Harrison, David J., Coyle, Vicky M., Graham, Jill, Jeffry Evans, Thomas R., Blagden, Sarah P.

المصدر: Spiliopoulou , P , Kazmi , F , Aroldi , F , Holmes , T , Thompson , D , Griffiths , L , Qi , C , Parkes , M , Lord , S , Veal , G J , Harrison , D J , Coyle , V M , Graham , J , Jeffry Evans , T R & Blagden , S P 2024 , ' A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301) ' , Journal of Experimental & Clinical Cancer Research , vol. 43 ....

مصطلحات موضوعية: NUC-3373, 5-FU, 5-fluorouracil, Fluoropyrimidines, Thymidylate synthase, Resistant cancer

وصف الملف: application/pdf

العلاقة: https://research-portal.st-andrews.ac.uk/en/researchoutput/a-phase-i-openlabel-doseescalation-study-of-nuc3373-a-targeted-thymidylate-synthase-inhibitor-in-patients-with-advanced-cancer-nutide301Test(27ec498d-bc27-4d39-87d8-b4103dff84ba).html

الإتاحة: https://doi.org/10.1186/s13046-024-03010-1Test
https://research-portal.st-andrews.ac.uk/en/researchoutput/a-phase-i-openlabel-doseescalation-study-of-nuc3373-a-targeted-thymidylate-synthase-inhibitor-in-patients-with-advanced-cancer-nutide301Test(27ec498d-bc27-4d39-87d8-b4103dff84ba).html
https://research-repository.st-andrews.ac.uk/bitstream/10023/29592/1/Spiliopoulou_2024_JECCR_Phase-I-open-label_CC.pdfTest

المؤلفون: Dixon-Zegeye, Miriam, Shaw, Rachel, Collins, Linda, Perez-Smith, Kendra, Ooms, Alexander, Qiao, Maggie, Pantziarka, Pan, Izatt, Louise, Tischkowitz, Marc, Harrison, Rachel E, George, Angela, Woodward, Emma R, Lord, Simon, Hawkes, Lara, Evans, D Gareth, Franklin, James, Hanson, Helen, Blagden, Sarah P

مصطلحات موضوعية: Cancer, Chemoprevention, LFS, Li-Fraumeni syndrome, Metformin, Precision-Prevention, TP53, p53, Adult, Humans, Mice, Animals, Quality of Life, Germ-Line Mutation, Magnetic Resonance Imaging, Genetic Predisposition to Disease, Randomized Controlled Trials as Topic, Clinical Trials, Phase II as Topic

وصف الملف: application/pdf

العلاقة: https://www.repository.cam.ac.uk/handle/1810/366650Test

الإتاحة: https://www.repository.cam.ac.uk/handle/1810/366650Test

المؤلفون: Janku, Filip, Choong, Grace M, Opyrchal, Mateusz, Dowlati, Afshin, Hierro, Cinta, Rodon, Jordi, Wicki, Andreas, Forster, Martin D, Blagden, Sarah P, Yin, Jun, Reid, Joel M, Muller, Helene, Cmiljanovic, Natasa, Cmiljanovic, Vladimir, Adjei, Alex A

المصدر: Cancers , 16 (6) , Article 1137. (2024)

مصطلحات موضوعية: PI3K/mTOR inhibitor, clinical trial, solid tumor, safety, intermittent dosing schedule

وصف الملف: text

العلاقة: https://discovery.ucl.ac.uk/id/eprint/10190777/1/cancers-16-01137-v3.pdfTest; https://discovery.ucl.ac.uk/id/eprint/10190777Test/

الإتاحة: https://discovery.ucl.ac.uk/id/eprint/10190777/1/cancers-16-01137-v3.pdfTest
https://discovery.ucl.ac.uk/id/eprint/10190777Test/

المؤلفون: Zhang, Ping, Kitchen-Smith, Isaac, Xiong, Lingyun, Stracquadanio, Giovanni, Brown, Katherine, Richter, Philipp H, Wallace, Marsha D, Bond, Elisabeth, Sahgal, Natasha, Moore, Samantha, Nornes, Svanhild, De Val, Sarah, Surakhy, Mirvat, Sims, David, Wang, Xuting, Bell, Douglas A, Zeron-Medina, Jorge, Jiang, Yanyan, Ryan, Anderson J, Selfe, Joanna L, Shipley, Janet, Kar, Siddhartha, Pharoah, Paul D, Loveday, Chey, Jansen, Rick, Grochola, Lukasz F, Palles, Claire, Protheroe, Andrew, Millar, Val, Ebner, Daniel V, Pagadala, Meghana, Blagden, Sarah P, Maughan, Timothy S, Domingo, Enric, Tomlinson, Ian, Turnbull, Clare, Carter, Hannah, Bond, Gareth L

المصدر: Cancer Research. 81(7)

مصطلحات موضوعية: Clinical Research, Cancer, Prevention, Human Genome, Patient Safety, Genetics, Biotechnology, Digestive Diseases, 2.1 Biological and endogenous factors, Aetiology, Animals, Antineoplastic Agents, Biomarkers, Pharmacological, Carcinogenesis, Case-Control Studies, Cell Line, Tumor, Disease Progression, Drug Resistance, Neoplasm, Female, Genetic Predisposition to Disease, Genome-Wide Association Study, Germ-Line Mutation, Humans, Male, Mice, Mice, Inbred BALB C, Mice, Nude, Mutation, Missense, Neoplasms, Polymorphism, Single Nucleotide, Prognosis, Risk Factors, Signal Transduction, Treatment Outcome, Tumor Suppressor Protein p53, Oncology and Carcinogenesis, Oncology & Carcinogenesis

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/4gc681tcTest

المؤلفون: Lythgoe, Mark P, Krell, Jonathan, Bower, Mark, Murphy, Ravindhi, Marriott, John, Blagden, Sarah P, Aggarwal, Ajay, Sullivan, Richard

وصف الملف: text

العلاقة: https://researchonline.lshtm.ac.uk/id/eprint/4669438/3/Lythgoe-etal-From-the-European-Medicines-Agency-to-Project-Orbis.pdfTest; Lythgoe, Mark P; Krell, Jonathan; Bower, Mark; Murphy, Ravindhi; Marriott, John; Blagden, Sarah P; Aggarwal, Ajay ; Sullivan, Richard; (2023) From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit. The Lancet. Oncology, 24 (4). e150-e160. ISSN 1470-2045 DOI: https://doi.org/10.1016/S1470-2045Test(22)00701-X

الإتاحة: https://doi.org/10.1016/s1470-2045Test(22)00701-x
https://doi.org/10.1016/S1470-2045Test(22)00701-X
https://researchonline.lshtm.ac.uk/id/eprint/4669438Test/
https://researchonline.lshtm.ac.uk/id/eprint/4669438/3/Lythgoe-etal-From-the-European-Medicines-Agency-to-Project-Orbis.pdfTest

المؤلفون: Luke, Jason J., Fakih, Marwan, Schneider, Charles, Chiorean, E. Gabriela, Bendell, Johanna, Kristeleit, Rebecca, Kurzrock, Razelle, Blagden, Sarah P., Brana, Irene, Goff, Laura W., O’Hayer, Kevin, Geschwindt, Ryan, Smith, Michael, Zhou, Feng, Naing, Aung

المساهمون: Incyte Corporation

المصدر: British Journal of Cancer ; volume 128, issue 12, page 2227-2235 ; ISSN 0007-0920 1532-1827

مصطلحات موضوعية: Cancer Research, Oncology

الإتاحة: https://doi.org/10.1038/s41416-023-02267-1Test
https://www.nature.com/articles/s41416-023-02267-1.pdfTest
https://www.nature.com/articles/s41416-023-02267-1Test

المؤلفون: Dickson, Alison L., Zickuhr, Greice M., Um, In Hwa, Zhang, Ying, Plummer, Ruth, Blagden, Sarah P., Symeonides, Stefan N., Cook, Natalie, Evans, T.R. Jeffry, Elshani, Mustafa, Harrison, David J.

العلاقة: Dickson, A. L. et al. (2024) Exposing the heterogeneity of the lipidome in the TME of cutaneous melanoma following treatment with NUC-7738 in combination with anti-PD-1 therapy. American Association for Cancer Research Annual Meeting 2024, San Diego, California, USA, 5-10 Apr 2024. p. 6222. (doi:10.1158/1538-7445.am2024-6222 )

الإتاحة: https://doi.org/10.1158/1538-7445.am2024-6222Test
https://eprints.gla.ac.uk/323599Test/

المؤلفون: Blagden, Sarah P, Yu, Ly-Mee, Ellis, Stephanie, Hughes, Helen, Shaaban, Abeer, Fennelly-Barnwell, Jonathan, Lythgoe, Mark P, Cooper, Alison M, Maignen, Francois M, Buckland, Sean W, Kearns, Pamela R, Brown, Louise C, Experimental Cancer Medicine Centres (ECMC) CID trials working g

المصدر: British Journal of Cancer (2022) (In press).

وصف الملف: text

العلاقة: https://discovery.ucl.ac.uk/id/eprint/10161325/1/s41416-022-02051-7.pdfTest; https://discovery.ucl.ac.uk/id/eprint/10161325Test/

الإتاحة: https://discovery.ucl.ac.uk/id/eprint/10161325/1/s41416-022-02051-7.pdfTest
https://discovery.ucl.ac.uk/id/eprint/10161325Test/

المؤلفون: Nicum, Shibani, Blagden, Sarah P

المصدر: Clinical Cancer Research , 28 (11) pp. 2201-2203. (2022)

وصف الملف: text

العلاقة: https://discovery.ucl.ac.uk/id/eprint/10146748/1/ccr-22-0442.pdfTest; https://discovery.ucl.ac.uk/id/eprint/10146748Test/

الإتاحة: https://discovery.ucl.ac.uk/id/eprint/10146748/1/ccr-22-0442.pdfTest
https://discovery.ucl.ac.uk/id/eprint/10146748Test/

المؤلفون: Davis, Elizabeth J, Martín Liberal, Juan Jesús, Kristeleit, Rebecca S, Cho, Daniel, Blagden, Sarah P, Berthold, Dominik, Vieito Villar, Maria

المساهمون: Institut Català de la Salut, Davis EJ Vanderbilt University Medical Center, Nashville, Tennessee, USA. Martin-Liberal J, Vieito M Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Kristeleit R Research Department of Oncology, University College London, London, UK. Cho DC Perlmutter Cancer Center, NYU Langone Health, NYU Grossman School of Medicine, New York, USA. Blagden SP Department of Oncology, University of Oxford, Oxford, UK. Berthold D Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Càncer - Tractament, Avaluació de resultats (Assistència sanitària), Medicaments antineoplàstics - Ús terapèutic, DISEASES::Neoplasms, Other subheadings::Other subheadings::Other subheadings::/drug therapy, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome, CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents, ENFERMEDADES::neoplasias, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento, COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos

وصف الملف: application/pdf

العلاقة: Journal for ImmunoTherapy of Cancer;10(10); http://dx.doi.org/10.1136/jitc-2021-004235Test; Davis EJ, Martin-Liberal J, Kristeleit R, Cho DC, Blagden SP, Berthold D, et al. First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors. J Immunother Cancer. 2022 Oct;10(10):e004235.; https://hdl.handle.net/11351/8540Test; 000877526500002

الإتاحة: https://doi.org/10.1136/jitc-2021-004235Test
https://hdl.handle.net/11351/8540Test